Introduction {#sec1_1}
============

Zellweger spectrum disorders (ZSDs; severe OMIM \#214100, mild OMIM \#601539) are a subgroup within peroxisomal biogenesis disorders. ZSDs have a generalized defect in peroxisome function that impairs fatty acid β-oxidation and bile acid synthesis, reduces bile flow due to reduced C~24~-primary bile acids, and results in accumulation of hepatotoxic C~27~-bile acids (dihydroxycholestanoic and trihydroxycholestanoic acid), potentially leading to progressive liver injury \[[@B1], [@B2]\]. Patients across the ZSD severity spectrum show a wide range of clinical symptoms, including mild to moderate or severe developmental delay, neurological abnormalities, vision and hearing impairment, liver dysfunction, and hepatomegaly \[[@B3]\]. Patient survival varies by ZSD severity, with mild ZSD patients surviving into adulthood, patients with moderate ZSD possibly surviving to their teens, and patients with the most severe form of ZSD typically not surviving beyond their first year \[[@B1]\].

The dysregulation of bile acid synthesis in ZSDs derives from the absence of peroxisomal β-oxidation of C~27~-bile acid intermediates, which prevents side-chain oxidation and formation of normal C~24~-primary bile acids, leading to the loss of normal feedback regulation of bile acid synthesis \[[@B2]\]. The resulting further production and accumulation of C~27~-bile acid intermediates has been linked with progressive liver disease \[[@B4]\]. Adjunctive treatment of ZSD with primary bile acid, oral cholic acid (CA; Cholbam®, Retrophin, Inc., San Diego, CA, USA), restores physiologic feedback inhibition on bile acid synthesis by activation of the nuclear receptor farnesoid X receptor (FXR) \[[@B5]\]. This reduces transcriptional activation of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid biosynthesis. The result is the inhibition of formation of hepatotoxic C~27~-bile acid intermediates from cholesterol \[[@B4], [@B5]\]. Downregulation of bile acid synthesis with reduction in levels of C~27~-bile acid intermediates during CA therapy was first demonstrated more than 20 years ago in an infant with severe ZSD \[[@B6]\] and has been shown more recently in ZSD patients following CA treatment for 9 months \[[@B2]\] and during long-term CA therapy \[[@B7]\].

Case Report {#sec1_2}
===========

We present the long-term CA treatment of a male Caucasian diagnosed at age 5 months with moderately severe ZSD (formerly known as neonatal adrenoleukodystrophy), with development of hepatocellular carcinoma (HCC) at age 19 years. Our patient was initially treated with CA within an investigator-initiated compassionate use program (NCT00007020) that was followed by an open-label, nonrandomized, noncomparative clinical study (NCT01438411). These studies were approved by the Institutional Review Board of the Cincinnati Children\'s Hospital Medical Center, and the patient\'s parents provided informed consent for inclusion. Within these studies, our patient received clinical care from his local health care providers and data collection was not required at standardized time points. Study-related laboratory assessments included the serum liver chemistries alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), and bilirubin. Additionally, a percutaneous liver biopsy was completed before initiation of CA treatment and 5 months following onset of CA treatment. Mass spectral analysis of urinary bile acids was performed, with fast atom bombardment ionization-mass spectrometry (FAB-MS) at the time of study entry to verify eligibility for study inclusion. FAB-MS was repeated throughout the study to monitor atypical urinary bile acid levels and used semi-quantitative assessment of normal, slight/mild, or significant/moderate increased levels of atypical bile acids.

At ZSD diagnosis, our patient had cholestasis with elevated urinary bile acids and markedly elevated serum liver enzymes but with a normal serum bilirubin (Table [1](#T1){ref-type="table"}). Two liver biopsies were performed before CA therapy. The first biopsy (age 4 months) had findings consistent with cholestasis, hepatocellular necrosis with presence of giant cells, periportal inflammation, and moderate fibrosis. The second biopsy (age 16 months) had reduced cholestasis, but with persistent hepatocellular necrosis, periportal inflammation, and progression to bridging fibrosis.

He received CA therapy (135 mg/day \[10 mg/kg/day\], increased to 300 mg/day \[15 mg/kg/day\]) over the course of 18 years and 6 months, beginning at age 16 months. No treatment-related adverse effects were reported. Liver biopsy following 5 months of CA therapy showed improvement in inflammation and no change in fibrosis (Fig. [1a](#F1){ref-type="fig"}). He showed normalization of urinary bile acids from CA initiation through age 4 years, followed by moderate elevation of urinary bile acids between ages 5 and 6 years, and a return to slight/mild elevation or normalized urinary bile acids thereafter (Fig. [2](#F2){ref-type="fig"}). He demonstrated profound developmental disability with no change during CA therapy.

Serum liver enzymes during CA therapy were less abnormal compared with pre-CA levels but frequently were above the upper limit of normal (Table [1](#T1){ref-type="table"}). The last available serum liver chemistries, following 18.5 years of CA therapy, were obtained when he presented with worsening jaundice, was diagnosed with HCC (Fig. [1b](#F1){ref-type="fig"}), and died 1 month later. For years prior to HCC diagnosis, he had clinical cirrhosis with severe portal hypertension, manifested by splenomegaly and esophageal varices requiring treatment with variceal band ligation and propranolol.

Discussion/Conclusion {#sec1_3}
=====================

In ZSD patients, development of chronic liver disease involving fibrosis and cirrhosis requires patient survival that is long enough for the advancement of the liver disease \[[@B8]\]. HCC in our 19-year-old patient was likely caused by his early-onset advanced liver disease (such as cirrhosis, a key risk factor for HCC \[[@B9]\]) and by potential carcinogenic effects of the natural disease progression of ZSD (such as accumulating dihydroxycholestanoic and trihydroxycholestanoic acid \[[@B5]\]; Fig. [3](#F3){ref-type="fig"}) that are not completely suppressed with CA treatment \[[@B10]\], as shown in the intermittent urinary bile acid elevations in our patient. To our knowledge, there are no prior published reports of HCC in ZSD patients. This is surprising as the natural disease progression may increase HCC risk, as indicated by mouse models of peroxisome biogenesis defects \[[@B11]\]. As depicted in the overview of liver metabolic abnormalities in mice with peroxisome biogenesis defects shown in Figure [3](#F3){ref-type="fig"}, metabolite alterations may be a direct consequence of peroxisome inactivity (e.g., bile acids) or secondary due to activation of proliferator-activated receptor alpha target genes, altered cholesterol homeostasis, and energy metabolism. Together this results in steatosis and steatohepatitis. The hypothesized increased carcinogenesis risk occurs through multiple metabolic deregulation pathways involving hepatotoxicity of accumulating C~27~-bile acid intermediates (e.g., dihydroxycholestanoic and trihydroxycholestanoic acid) and pathways independent of bile acids, such as proliferator-activated receptor alpha activation and increased endoplasmic reticulum stress \[[@B11]\]. Additionally, in another example of increased HCC risk as the ZSD disease progresses, a ZSD mouse model with hepatocyte-selective elimination of peroxisomes showed early severe hepatomegaly and fibrosis and extensive liver tumors by 12 months \[[@B12]\].

C~27~-bile acid intermediates may also play an important role in the neurological symptoms associated with ZSDs. It is hypothesized that C~27~-bile acid intermediates cross the blood-brain barrier and damage the central nervous system \[[@B3]\]. In support of this hypothesis, brain tissues from patients with a peroxisome deficiency disorder were found to have increased C~27~-bile acids, specifically unconjugated dihydroxycholestanoic and trihydroxycholestanoic acid, compared with controls \[[@B5]\]. Further, ZSD mouse models have shown impairments in developing neocortex and cerebellum and in brain neuronal migration \[[@B13]\], and bile acid treatment partially restored cerebellar abnormalities \[[@B14]\].

Our experience with CA therapy in this patient with advanced liver disease differed from the 4 ZSD patients with advanced liver disease reported by Berendse et al. \[[@B2]\]. In contrast to the poor response seen by Berendse, our patient responded to CA treatment with a reduction in serum aminotransferases and initial normalization of urinary bile acids. No hepatotoxic effects were evident, and serum bilirubin remained normal until the onset of HCC. A possible explanation for the improved response in our patient is his younger age at CA treatment initiation (16 months old vs. the 4- to 10-year-old patients described by Berendse et al. \[[@B2]\]).

Long-term CA therapy appears to have been well tolerated in our patient with moderately severe ZSD without report of side effects and with continuation of therapy over 18 years. In our patient case, treatment-related adverse events were not systematically collected. Rather, side effects were reported by the patient\'s family as needed. The registration trial that supported FDA approval of CA was conducted over 18 years and included patients with ZSD and bile acid synthesis disorders due to single-enzyme defects. Within the registration trial, the most common treatment-emergent adverse events were diarrhea, urinary tract infection, and dehydration \[[@B7]\].

Early, long-term CA therapy in ZSD patients may help sustain liver function, as suggested by a significant increase in the percentage of ZSD patients showing normalized urinary bile acids and serum liver enzyme levels that stabilized or were within normal limits following long-term treatment in the registration trial that supported FDA approval of CA \[[@B7]\], including 3 patients whose individual CA treatment history and liver-related outcomes over long-term CA therapy were recently reported \[[@B15]\]. Liver synthetic function in our patient reported here was maintained during 18 years of CA therapy, but CA treatment did not affect his profound neurologic injury or prevent development of portal hypertension, clinical cirrhosis, and HCC. Our patient survived to an older age than is typically reported for patients with moderately severe ZSD. Whether CA therapy contributed to his survival could not be determined in this patient. Further studies are needed, particularly in patients with early initiation of treatment, to elucidate the potential long-term hepatic and extrahepatic effects of CA therapy. Early-onset advanced liver disease associated with his moderately severe ZSD and natural disease progression that is not completely suppressed with CA treatment likely caused HCC in our patient. Greater awareness is needed of the possibility of development of HCC in patients with moderately severe ZSD who survive past childhood.
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![**a** Liver biopsy at age 2 years shows periportal fibrosis with septa formation and pericellular fibrosis. Hepatocytes are slightly swollen and inflammation is minimal. Masson Trichrome stain. **Inset** shows scattered enlarged sinusoidal macrophages containing PAS+ inclusions. Diastase-PAS stain. **b** MRI image reveals small liver containing two well-defined tumor masses interpreted as HCC.](crg-0012-0661-g01){#F1}

![Highest level of urinary bile acid during each year of cholic acid (CA) treatment. Urinary bile acid was assessed ≥1 time each year through 16 years of treatment. The highest value obtained in each year is shown. The FAB-MS mass spectra at baseline and post-treatment were assessed as normal (score 0) or as showing slight (score 1), significant (score 2), or marked (score 3) increases in the levels of atypical bile acids \[[@B7]\].](crg-0012-0661-g02){#F2}

![Overview of metabolic abnormalities reported in liver of mice with peroxisome biogenesis defects. Reprinted with permission from Baes and Van Veldhoven \[[@B11]\]. AMPK, AMP-activated protein kinase; DCA, dichloroacetate; DHA, docosahexaenoic acid; ER, endoplasmic reticulum; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα, proliferator-activated receptor alpha; VLCFA, very long chain fatty acids.](crg-0012-0661-g03){#F3}
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Serum liver chemistries during long-term cholic acid therapy in a patient with Zellweger spectrum disorder

                                                                                                                                                                                                                                                                                                    ALT, U/L (RR)         AST, U/L (RR)          ALP, U/L (RR)            GGT, U/L (RR)           Total bilirubin, mg/dL (RR)   PT, s (RR)                  INR
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ---------------------- ------------------------ ----------------------- ----------------------------- --------------------------- -----
  Pre-CA (age 3--5 months)                                                                                                                                                                                                                                                                          **184 (4**--**35)**   **299 (10**--**50)**   **560 (82**--**383)**    **191 (12**--**122)**   0.8 (0.2--1.0)                11 (9--13)                  1.0
  Pre-CA (age 1 year, 4 months)                                                                                                                                                                                                                                                                     **257 (4**--**35)**   **146 (10**--**50)**   349 (82**--**383)        **73 (1**--**39)**      0.5 (0.2--1.0)                12.4 (9--13)                1.2
  5-month CA therapy                                                                                                                                                                                                                                                                                **95 (5**--**30)**    **220 (10**--**50)**   **379 (104**--**345)**   **49 (3**--**22)**      0.4 (0.2--1.0)                NA                          NA
  2-year 9-month CA therapy                                                                                                                                                                                                                                                                         **49 (5**--**20)**    NA                     NA                       **124 (3**--**22)**     0.6 (0.2--1.0)                12 (11--14)                 1.0
  7-year 3-month CA therapy                                                                                                                                                                                                                                                                         **44 (0**--**39)**    **69 (0**--**33)**     223 (\<300)              NA                      0.7 (0.2--1.0)                **13.5 (10.1**--**13.1)**   1.1
  12-year 9-month CA therapy                                                                                                                                                                                                                                                                        **79 (30**--**65)**   **97 (15**--**37)**    **274 (52**--**171)**    **243 (15**--**85)**    0.7 (0.0--1.0)                **12 (9.0**--**11.4)**      1.2
  14-year 9-month CA therapy                                                                                                                                                                                                                                                                        **99 (30**--**65)**   **91 (15**--**37)**    **474 (50**--**136)**    **233 (15**--**85)**    0.9 (0.0--1.0)                NA                          NA
  16-year 11-month CA therapy                                                                                                                                                                                                                                                                       71 (\<78)             **76 (\<37)**          **245 (\<117)**          NA                      0.9 (0.0--1.0)                **13.1 (9.4**--**12.9)**    1.2
  18-year 6-month CA therapy                                                                                                                                                                                                                                                                        **92 (0**--**41)**    NA                     **309 (40**--**129)**    **278 (8**--**61)**     **3.8 (\<1.2)**               12 (9--12)                  1.2
                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA, cholic acid; GGT, gamma-glutamyl transpeptidase; INR, international normalized ratio; NA, not available; PT, prothrombin time; RR, reference range. Bolded values are above the reference range.                                                                                                                                                           
